Brought to you by 
GSK and Verily Life Sciences form new joint venture Galvani Bioelectronics
27 Jan 2023
Executive Summary
GlaxoSmithKline PLC and Verily Life Sciences LLC formed a new joint venture company Galvani Bioelectronics focusing on bioelectronic medicines. The two parent companies will contribute existing IP rights and invest up to £540mm ($702mm) over a seven-year term (subject to completion of discovery and development milestones).
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Biosensors
-
Biotechnology
- Drug Discovery Technologies
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK and Verily Life Sciences form new joint venture Galvani Bioelectronics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice